Welcome to LookChem.com Sign In|Join Free

CAS

  • or

93-35-6

Post Buying Request

93-35-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

93-35-6 Usage

Chemical Properties

Light Brownish Powder

Uses

Different sources of media describe the Uses of 93-35-6 differently. You can refer to the following data:
1. A metabolite of Coumarin. The aglucon of skimmin. Present in many plants
2. antifungal, phytoalexin
3. In sunscreen lotions and creams; as intracellular and pH sensitive fluorescent indicator and blood-brain barrier probe.
4. 7-Hydroxycoumarin is used as an intracellular pH sensitive fluorescent indicator & bloodbrain barrier probe. It is used as a sunscreen agent, and an optical brightener for textiles. It has also been used as a gain medium for dye lasers.

Definition

ChEBI: A hydroxycoumarin that is coumarin substituted by a hydroxy group ay position 7.

General Description

Umbelliferone is a naturally occurring coumarin, present in a variety of medicinal plants from the Apiaceae (Umbelliferae) family and also in plants from other families such as mouse-ear hawkweed.

Purification Methods

It crystallises from water (m 232-232.2o) or EtOH (m 232o). It sublimes at 160o/0.001mm. Fluorescence: Em max 452nm/Exc 325nm in 50% EtOH. [Beilstein 18 H 27, 18 I 306, 18 II 16, 18 III/IV 294, 18/1 V 386.]

Check Digit Verification of cas no

The CAS Registry Mumber 93-35-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 9 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 93-35:
(4*9)+(3*3)+(2*3)+(1*5)=56
56 % 10 = 6
So 93-35-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H6O3/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5,10H

93-35-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (H0236)  Umbelliferone  >98.0%(GC)

  • 93-35-6

  • 5g

  • 200.00CNY

  • Detail
  • TCI America

  • (H0236)  Umbelliferone  >98.0%(GC)

  • 93-35-6

  • 25g

  • 595.00CNY

  • Detail
  • Alfa Aesar

  • (L04082)  7-Hydroxycoumarin, 98%   

  • 93-35-6

  • 25g

  • 401.0CNY

  • Detail
  • Alfa Aesar

  • (L04082)  7-Hydroxycoumarin, 98%   

  • 93-35-6

  • 100g

  • 1341.0CNY

  • Detail
  • Vetec

  • (V900776)  Umbelliferone  Vetec reagent grade, 98%

  • 93-35-6

  • V900776-25G

  • 179.01CNY

  • Detail
  • Vetec

  • (V900776)  Umbelliferone  Vetec reagent grade, 98%

  • 93-35-6

  • V900776-100G

  • 573.30CNY

  • Detail
  • Aldrich

  • (H24003)  Umbelliferone  99%

  • 93-35-6

  • H24003-10G

  • 226.98CNY

  • Detail
  • Aldrich

  • (H24003)  Umbelliferone  99%

  • 93-35-6

  • H24003-25G

  • 360.36CNY

  • Detail
  • Aldrich

  • (H24003)  Umbelliferone  99%

  • 93-35-6

  • H24003-100G

  • 2,204.28CNY

  • Detail
  • Sigma

  • (93979)  Umbelliferone  suitable for fluorescence indicator, ≥98.0% (HPLC)

  • 93-35-6

  • 93979-25G

  • 753.48CNY

  • Detail
  • Sigma

  • (93979)  Umbelliferone  suitable for fluorescence indicator, ≥98.0% (HPLC)

  • 93-35-6

  • 93979-100G

  • 2,511.99CNY

  • Detail
  • Sigma-Aldrich

  • (54826)  Umbelliferone  analytical standard

  • 93-35-6

  • 54826-50MG

  • 329.94CNY

  • Detail

93-35-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name umbelliferone

1.2 Other means of identification

Product number -
Other names UMBELLIFERON

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:93-35-6 SDS

93-35-6Synthetic route

5-hydroxy-2-vinylphenyl acrylate
1516900-23-4

5-hydroxy-2-vinylphenyl acrylate

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride In dichloromethane at 37℃; for 24h; Reagent/catalyst; Solvent;99%
7-(benzyloxy)-2H-chromen-2-one
31005-04-6

7-(benzyloxy)-2H-chromen-2-one

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With boron trifluoride diethyl etherate; ethanethiol In dichloromethane at 30℃; for 72h;98.8%
With boron trifluoride diethyl etherate; ethanethiol In dichloromethane at 30℃; for 72h; Product distribution; Other reagent: Me2S instead of EtSH. Investigation of the debenzylation of the 4-methyl derivative.;98.8%
With iodine In 2,2'-[1,2-ethanediylbis(oxy)]bisethanol at 120℃; for 2h;70%
7-prenyloxycoumarin
10387-50-5

7-prenyloxycoumarin

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With toluene-4-sulfonic acid In dichloromethane at 20℃; for 1h;98%
at 200℃;
7-methoxycoumarin
531-59-9

7-methoxycoumarin

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With Pyridine hydrobromide In sulfolane at 150 - 160℃; for 7h; Inert atmosphere;98%
With aluminum (III) chloride In toluene for 3h; Reflux;86%
With 1-n-butyl-3-methylimidazolim bromide; toluene-4-sulfonic acid; 1-butyl-3-methylimidazolium Tetrafluoroborate at 115℃; for 13h;80%
7-allyloxycoumarin
31005-03-5

7-allyloxycoumarin

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With ammonium formate; palladium on activated charcoal In methanol for 1h; Heating;98%
With boron trichloride; tetra-(n-butyl)ammonium iodide In dichloromethane at -78 - 20℃; for 2h; dealkylation;96%
Multi-step reaction with 4 steps
1.1: ozone; DMF / CH2Cl2 / -30 °C
1.2: 62 percent / dimethylsulfide
2.1: rabbit muscle aldolase; (2-hydroxypropyl)-β-cyclodextrin / 48 h / 20 °C / pH 7.5
2.2: 35 percent / acid phoshatase / pH 4.8
3.1: transketolase extract
4.1: bovine serum albumin; Tris buffer / pH 8.2
View Scheme
7-acetyloxycoumarin
10387-49-2

7-acetyloxycoumarin

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With methanol; zinc97%
With sodium hydrogen telluride; acetic acid In ethanol for 0.5h; Heating;90%
With mesoporous silica-supported (Salen) Co(II) catalyst In methanol at 20℃; for 1.5h; chemoselective reaction;90%
With entrapped lipase-PEG In hexane; isopropyl alcohol at 36℃; Enzyme kinetics; Further Variations:; Reagents;
malic acid
617-48-1

malic acid

recorcinol
108-46-3

recorcinol

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With sulfuric acid for 0.0583333h; Microwave irradiation;92%
With sulfuric acid at 100℃; for 2.5h;74.2%
With sulfuric acid at 20 - 100℃; for 3h; von Pechmann Cycloaddition;71%
Propiolic acid
471-25-0

Propiolic acid

recorcinol
108-46-3

recorcinol

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With ytterbium(III) trifluoromethanesulfonate hydrate at 80℃; for 0.0333333h; Reagent/catalyst; Microwave irradiation;92%
With para-chlorotoluene; zeolite H-beta at 150℃; for 20h;60%
With H-BEA In various solvent(s) at 150℃; for 20h;60%
With iron(III) chloride; silver trifluoromethanesulfonate; trifluoroacetic acid In 1,2-dichloro-ethane at 30℃; for 15h;59%
With iron(III) chloride; silver trifluoromethanesulfonate In 1,2-dichloro-ethane; trifluoroacetic acid at 30℃;55%
Resorcinol monoacetate
102-29-4

Resorcinol monoacetate

acrylic acid methyl ester
292638-85-8

acrylic acid methyl ester

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With formic acid; rhodium(II) acetate dimer; sodium acetate In neat (no solvent) at 100℃; for 3h; Molecular sieve; Inert atmosphere; regioselective reaction;92%
7-furoyloxycoumarin
94739-97-6

7-furoyloxycoumarin

A

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

B

8-(Furan-2-carbonyl)-7-hydroxy-chromen-2-one
94740-05-3

8-(Furan-2-carbonyl)-7-hydroxy-chromen-2-one

C

6-(Furan-2-carbonyl)-7-hydroxy-chromen-2-one
94740-04-2

6-(Furan-2-carbonyl)-7-hydroxy-chromen-2-one

Conditions
ConditionsYield
In ethanol for 48h; Irradiation;A 90%
B 80 mg
C 170 %
In ethanol for 48h; Irradiation;A 90 mg
B 80 mg
C 170 mg
In ethanol for 48h; Irradiation;A 90 mg
B 80 mg
C 170 mg
7-ethoxymethoxychromen-2-one

7-ethoxymethoxychromen-2-one

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With boron trichloride; tetra-(n-butyl)ammonium iodide In dichloromethane at -78℃; for 1h; dealkylation;90%
7-(methoxymethoxy)-2H-chromen-2-one
80754-21-8

7-(methoxymethoxy)-2H-chromen-2-one

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With toluene-4-sulfonic acid In neat (no solvent, solid phase) at 20℃; for 0.583333h; Green chemistry;90%
chloroacetic acid ethyl ester
105-39-5

chloroacetic acid ethyl ester

2,4-Dihydroxybenzaldehyde
95-01-2

2,4-Dihydroxybenzaldehyde

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With molecular sieve; sodium methylate; triphenylphosphine Wittig reaction; microwave irradiation;88%
With sodium methylate; magnesium oxide; triphenylphosphine Wittig reaction;85%
methyl chloroacetate
96-34-4

methyl chloroacetate

2,4-Dihydroxybenzaldehyde
95-01-2

2,4-Dihydroxybenzaldehyde

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With sodium methylate; triphenylphosphine at 80 - 210℃; for 5.5h; Ionic liquid;88%
propynoic acid ethyl ester
623-47-2

propynoic acid ethyl ester

recorcinol
108-46-3

recorcinol

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With zinc(II) chloride at 100℃; for 0.5h; neat (no solvent); regioselective reaction;85%
With indium(III) chloride at 90℃; for 2h; Michael addition;52%
Stage #1: propynoic acid ethyl ester; recorcinol With zinc(II) chloride In 1,4-dioxane for 24h; Reflux;
Stage #2: With hydrogenchloride In 1,4-dioxane; water
40%
In 1,4-dioxane for 24h; Reflux;
methyl chloroacetate
96-34-4

methyl chloroacetate

2,4-Dihydroxybenzaldehyde
95-01-2

2,4-Dihydroxybenzaldehyde

A

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

B

3-(2’,4’-dihydroxyphenyl)-(E)-propenoic acid methyl ester

3-(2’,4’-dihydroxyphenyl)-(E)-propenoic acid methyl ester

Conditions
ConditionsYield
With 1-(2-OPPh2-propyl)-3-methylimidazolium hexafluorophosphate; sodium methylate at 110℃; for 0.183333h; Horner-Wadsworth-Emmons olefination; Ionic liquid; Microwave irradiation;A 84%
B 16%
Propiolic acid
471-25-0

Propiolic acid

recorcinol
108-46-3

recorcinol

A

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

B

5-hydroxycoumarin
6093-67-0

5-hydroxycoumarin

Conditions
ConditionsYield
With trifluoroacetic acid In chlorobenzene at 100℃; for 6h; Inert atmosphere;A 81%
B 5%
With trifluorormethanesulfonic acid In chlorobenzene at 100℃; for 6h;A 81%
B 5%
Dowex 50x2-200 at 120℃; for 0.166667h; microwave irradiation (30 W);A 69%
B 31%
Dowex 50x2-200 at 120℃; for 0.166667h; Product distribution; microwave irradiation (30 W); other temperature and reaction time; also without microwave irradiation ; also under reflux in p-ClC6H4CH3 in the presence of Amberlyst;
ethyl acetoacetate
141-97-9

ethyl acetoacetate

2,4-Dihydroxybenzaldehyde
95-01-2

2,4-Dihydroxybenzaldehyde

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With piperidine In ethanol at 20℃; for 0.5h; Knoevenagel Condensation;75%
methyl (triphenylphosphoranylidene)acetate
21204-67-1

methyl (triphenylphosphoranylidene)acetate

2,4-Dihydroxybenzaldehyde
95-01-2

2,4-Dihydroxybenzaldehyde

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
Stage #1: methyl (triphenylphosphoranylidene)acetate; 2,4-Dihydroxybenzaldehyde In methanol at 20℃; Wittig Olefination;
Stage #2: In methanol at 40 - 50℃; for 9h; UV-irradiation;
74%
ethyl (triphenylphosphoranylidene)acetate
1099-45-2

ethyl (triphenylphosphoranylidene)acetate

2,4-Dihydroxybenzaldehyde
95-01-2

2,4-Dihydroxybenzaldehyde

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With N,N-diethylaniline for 0.25h; Heating;70%
ethyl (triphenylphosphoranylidene)acetate
1099-45-2

ethyl (triphenylphosphoranylidene)acetate

2,4-Dihydroxybenzaldehyde
95-01-2

2,4-Dihydroxybenzaldehyde

A

(E)-3-(2,4-dihydroxyphenyl)acrylic acid ethyl ester
149542-04-1

(E)-3-(2,4-dihydroxyphenyl)acrylic acid ethyl ester

B

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
In toluene at 60℃; Wittig reaction;A 70%
B n/a
4-Bromoresorcinol
6626-15-9

4-Bromoresorcinol

acrylic acid methyl ester
292638-85-8

acrylic acid methyl ester

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With palladium diacetate; potassium hydrogencarbonate at 140℃; for 0.233333h; Heck reaction; Microwave irradiation; neat (no solvent);70%
7-allyloxycoumarin
31005-03-5

7-allyloxycoumarin

A

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

B

7-(2-oxopropoxy)-2H-1-benzopyran-2-one
36914-75-7

7-(2-oxopropoxy)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
With oxygen; copper dichloride; palladium dichloride In water; N,N-dimethyl-formamide at 25℃; for 6h;A n/a
B 65%
2-(2,4-Dihydroxy-benzyl)-3,3-dimethyl-pent-4-enoic acid methyl ester
135656-81-4

2-(2,4-Dihydroxy-benzyl)-3,3-dimethyl-pent-4-enoic acid methyl ester

A

3-(1,1-dimethylallyl)-7-hydroxycoumarin
56881-08-4

3-(1,1-dimethylallyl)-7-hydroxycoumarin

B

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With palladium on activated charcoal In diphenylether Heating;A 25%
B 50%
7-(vinyloxy)-2H-chromen-2-one

7-(vinyloxy)-2H-chromen-2-one

3,6-di(2'-pyridyl)-1,2,4,5-tetrazine
1671-87-0

3,6-di(2'-pyridyl)-1,2,4,5-tetrazine

A

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

B

3,6-di(pyridin-2'-yl)-s-tetrazine
36901-11-8

3,6-di(pyridin-2'-yl)-s-tetrazine

Conditions
ConditionsYield
In dichloromethane at 20℃; for 72h; Inert atmosphere;A 47%
B 50%
(2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate

(2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With 4-(1,2,4,5-tetrazin-3-yl)benzoic acid In water; dimethyl sulfoxide at 37℃; Kinetics; Reagent/catalyst; Irradiation;39%
Propiolic acid
471-25-0

Propiolic acid

recorcinol
108-46-3

recorcinol

A

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

B

4,4'-(ethane-1,1-diyl)bis(benzene-1,3-diol)
432041-90-2

4,4'-(ethane-1,1-diyl)bis(benzene-1,3-diol)

Conditions
ConditionsYield
In water for 21h; Reflux;A 1%
B 27%
3-chloroacrylic acid
1609-93-4

3-chloroacrylic acid

recorcinol
108-46-3

recorcinol

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With H-BEA In toluene for 4h; Heating;12%
(E)-3-chloroacrylic acid
2345-61-1

(E)-3-chloroacrylic acid

recorcinol
108-46-3

recorcinol

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With H-BEA In toluene for 4h; Heating;12%
coumarin
91-64-5

coumarin

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Conditions
ConditionsYield
With dihydrogen peroxide; zirconium(IV) oxide In water5.7%
With human liver microsome at 37℃; for 0.25h; Kinetics; Oxidation; Enzymatic reaction;
With NADPH-generating system; recombinant human cytochrome P450 or CYP enzymes; dinoprostone In phosphate buffer pH=7.4; Enzyme kinetics; Further Variations:; Reagents; hydroxylation; Enzymatic reaction;
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

allyl bromide
106-95-6

allyl bromide

7-allyloxycoumarin
31005-03-5

7-allyloxycoumarin

Conditions
ConditionsYield
With potassium carbonate In acetone for 5h; Heating;100%
Stage #1: 7-hydroxy-2H-chromen-2-one With potassium carbonate In acetone at 20℃; for 0.0833333h;
Stage #2: allyl bromide In acetone for 3h; Reflux;
100%
With potassium carbonate In acetone at 70℃; for 12h;98.6%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

acetic anhydride
108-24-7

acetic anhydride

7-acetyloxycoumarin
10387-49-2

7-acetyloxycoumarin

Conditions
ConditionsYield
In pyridine; dichloromethane for 0.25h;100%
With SiO2-supported Co(II) Salen complex catalyst at 50℃; for 0.75h;99%
With pyridine In ethyl acetate at 20℃; for 1.5h; Inert atmosphere;99%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

1,3-dibromo-propane
109-64-8

1,3-dibromo-propane

7-(3-bromopropoxy)−2H-chromen-2-one
69150-28-3

7-(3-bromopropoxy)−2H-chromen-2-one

Conditions
ConditionsYield
With potassium carbonate In acetone for 12h; Reflux;100%
With potassium carbonate In acetonitrile Reflux;86.9%
With potassium carbonate In acetone Reflux;79%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

7-hydroxychroman-2-one
5631-67-4

7-hydroxychroman-2-one

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In acetic acid100%
With palladium 10% on activated carbon; hydrogen In acetic acid at 20℃; for 12h; Inert atmosphere;99%
With palladium 10% on activated carbon; hydrogen; acetic acid at 50℃; under 2550.26 Torr; for 17h;96.5%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

ethyl bromoacetate
105-36-2

ethyl bromoacetate

ethyl 2-((2-oxo-2H-chromen-7-yl)oxy)acetate
72000-18-1

ethyl 2-((2-oxo-2H-chromen-7-yl)oxy)acetate

Conditions
ConditionsYield
With potassium carbonate In acetone for 4h; Heating;100%
With potassium carbonate In acetone for 5h; Heating;98%
Stage #1: 7-hydroxy-2H-chromen-2-one With potassium carbonate In acetone for 0.5h;
Stage #2: ethyl bromoacetate In ethyl acetate at 20℃; for 6h;
96%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

2,6-dichloropyrazine
4774-14-5

2,6-dichloropyrazine

2-chloro-6-(7-coumarinyloxy)-pyrazine
894416-91-2

2-chloro-6-(7-coumarinyloxy)-pyrazine

Conditions
ConditionsYield
With potassium tert-butylate In N,N-dimethyl-formamide at 90℃; for 5h; Inert atmosphere;100%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

iodomethane-d3
865-50-9

iodomethane-d3

[methyl-2H3]7-methoxycoumarin

[methyl-2H3]7-methoxycoumarin

Conditions
ConditionsYield
With potassium carbonate In acetone100%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

3-bromo-7-hydroxy-2H-1-benzopyran-2-one
146900-52-9

3-bromo-7-hydroxy-2H-1-benzopyran-2-one

Conditions
ConditionsYield
With N-chloro-succinimide; copper(II) chloride monohydrate; zinc(II) chloride In acetonitrile at 20℃; for 0.0833333h; regioselective reaction;99.5%
With N-Bromosuccinimide at 20℃; for 2h; regioselective reaction;92%
With γ-picolinium bromochromate In acetonitrile at 90℃; for 1.66667h; regioselective reaction;83%
2-(2-bromoethoxy)tetrahydropyran
17739-45-6, 59146-56-4

2-(2-bromoethoxy)tetrahydropyran

7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

7-[2-(tetrahydro-2H-2-pyranyloxy)ethoxy]-2H-2-chromenone
201813-16-3

7-[2-(tetrahydro-2H-2-pyranyloxy)ethoxy]-2H-2-chromenone

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 60℃; Etherification;99%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Methyl 4-bromobutyrate
4897-84-1

Methyl 4-bromobutyrate

C14H14O5

C14H14O5

Conditions
ConditionsYield
With 18-crown-6 ether; potassium carbonate In N,N-dimethyl-formamide at 50℃; for 24h;99%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

1-halopropane

1-halopropane

7-propoxy-2H-chromen-2-one
6093-73-8

7-propoxy-2H-chromen-2-one

Conditions
ConditionsYield
With potassium carbonate In acetone at 80℃; for 1h;99%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

haloethane

haloethane

7-ethoxycoumarin
31005-02-4

7-ethoxycoumarin

Conditions
ConditionsYield
With potassium carbonate In acetone at 80℃; for 1h;99%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

halomethane

halomethane

7-methoxycoumarin
531-59-9

7-methoxycoumarin

Conditions
ConditionsYield
With potassium carbonate In acetone at 80℃; for 1h;99%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

3-bromophenyltrimethylammonium iodide

3-bromophenyltrimethylammonium iodide

7-methoxycoumarin
531-59-9

7-methoxycoumarin

Conditions
ConditionsYield
With potassium carbonate In dimethyl sulfoxide at 80℃; for 3h; Solvent;99%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

benzyl bromide
100-39-0

benzyl bromide

7-(benzyloxy)-2H-chromen-2-one
31005-04-6

7-(benzyloxy)-2H-chromen-2-one

Conditions
ConditionsYield
With potassium carbonate In acetone for 72h; Heating;98%
With potassium carbonate In acetone for 4h; Inert atmosphere; Reflux;95%
Stage #1: 7-hydroxy-2H-chromen-2-one With potassium carbonate In acetone for 0.25h; Inert atmosphere; Reflux;
Stage #2: benzyl bromide In acetone Inert atmosphere; Reflux;
91%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

umbelliprenine
23838-17-7

umbelliprenine

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran; dimethyl sulfoxide for 2h; Heating;98%
With potassium carbonate In acetone at 20℃; for 12h;83%
With potassium carbonate In acetone for 6h; Reflux;80%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

3-chloro-2-butanone
4091-39-8

3-chloro-2-butanone

7-((3-oxobutan-2-yl)oxy)-2H-chromen-2-one
156006-08-5

7-((3-oxobutan-2-yl)oxy)-2H-chromen-2-one

Conditions
ConditionsYield
With potassium carbonate; sodium iodide In acetone at 0 - 60℃;98%
With potassium carbonate In acetone for 24h; Heating;62%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

chloromethyl methyl ether
107-30-2

chloromethyl methyl ether

7-(methoxymethoxy)-2H-chromen-2-one
80754-21-8

7-(methoxymethoxy)-2H-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide; methyltrialkyl(C8-C10)ammonium chloride (Adogen 464) In dichloromethane for 2h;98%
Stage #1: 7-hydroxy-2H-chromen-2-one With sodium hydride In tetrahydrofuran; N,N-dimethyl-formamide at 0℃; for 3h; Inert atmosphere;
Stage #2: chloromethyl methyl ether In tetrahydrofuran; N,N-dimethyl-formamide at 0 - 20℃; for 17h; Inert atmosphere;
89.2%
With sodium hydride 1.) THF, DMF, RT, 3 h, 2.) THF, DMF, RT, 17 h; Yield given. Multistep reaction;
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

1-dodecylbromide
143-15-7

1-dodecylbromide

7-(dodecyloxy)coumarin
85389-85-1

7-(dodecyloxy)coumarin

Conditions
ConditionsYield
With potassium hydroxide In acetone for 24h; Reflux; Inert atmosphere;98%
With potassium hydroxide In acetone for 24h; Inert atmosphere; Reflux;98%
With potassium carbonate In N,N-dimethyl-formamide for 30h; Heating;60%
With potassium hydroxide In acetone at 68℃; for 24h; Inert atmosphere;
With potassium hydroxide In acetone at 68℃; for 24h; Inert atmosphere;
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

propargyl bromide
106-96-7

propargyl bromide

7-(propynyloxy)-2H-chromen-2-one
67268-42-2

7-(propynyloxy)-2H-chromen-2-one

Conditions
ConditionsYield
With potassium carbonate; potassium iodide In N,N-dimethyl-formamide at 80℃; for 2h;98%
With potassium carbonate In acetone for 8h; Reflux;97%
With potassium carbonate In acetone at 50℃; for 18h;95%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

Ethyl 2-bromopropionate
535-11-5, 41978-69-2

Ethyl 2-bromopropionate

ethyl 2-[(2-oxo-2H-chromen-7-yl)oxy]propanoate
314262-30-1

ethyl 2-[(2-oxo-2H-chromen-7-yl)oxy]propanoate

Conditions
ConditionsYield
With potassium carbonate In acetone for 5h; Heating;98%
Stage #1: 7-hydroxy-2H-chromen-2-one With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 0.333333h;
Stage #2: Ethyl 2-bromopropionate In N,N-dimethyl-formamide at 90℃; for 5h;
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

benzenesulfonyl chloride
98-09-9

benzenesulfonyl chloride

7-Hydroxycoumarin benzenesulfonate

7-Hydroxycoumarin benzenesulfonate

Conditions
ConditionsYield
With pyridine for 0.5h; Heating;98%
With pyridine for 0.5h;98%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

tert-butyl (1S,5S)-5-methyl-4-oxocyclohex-2-enyl carbonate
954390-26-2

tert-butyl (1S,5S)-5-methyl-4-oxocyclohex-2-enyl carbonate

7-((1S,5S)-5-methyl-4-oxocyclohex-2-enyloxy)-2H-chromen-2-one
1232680-29-3

7-((1S,5S)-5-methyl-4-oxocyclohex-2-enyloxy)-2H-chromen-2-one

Conditions
ConditionsYield
With tris(dibenzylideneacetone)dipalladium(0) chloroform complex; triphenylphosphine In dichloromethane at 0℃; Inert atmosphere;98%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

dimethyl acetylenedicarboxylate
762-42-5

dimethyl acetylenedicarboxylate

7-methoxycoumarin
531-59-9

7-methoxycoumarin

Conditions
ConditionsYield
With 1-methyl-1H-imidazole In neat (no solvent) at 100℃; for 0.0666667h; Microwave irradiation; Green chemistry;98%
7-hydroxy-2H-chromen-2-one
93-35-6

7-hydroxy-2H-chromen-2-one

8-halo-2,6-dimethylocta-2,6-diene

8-halo-2,6-dimethylocta-2,6-diene

7-(3,7-dimethylocta-2,6-dienyloxy)-2H-1-benzopyran-2-one
29527-66-0

7-(3,7-dimethylocta-2,6-dienyloxy)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
With potassium carbonate In acetone at 80℃; for 1h;98%

93-35-6Related news

XAFS study of bioactive Cu(II) complexes of 7-Hydroxycoumarin (cas 93-35-6) derivatives in organic solvents07/24/2019

We characterize the structure of two Cu(II) complexes of 7-hydroxycoumarins in organic solvents. The solvents are, dimethyl sulfoxide and dimethylformamide. X-ray absorption spectroscopy together with density functional theory calculations are employed to identify the structural changes induced ...detailed

Activation of β1-adrenoceptor triggers oxidative stress mediated myocardial membrane destabilization in isoproterenol induced myocardial infarcted rats: 7-Hydroxycoumarin (cas 93-35-6) and its counter action07/23/2019

Activation of β1-adrenoceptor stimulates myocardial membrane destabilization in isoproterenol induced rats. Male albino Wistar rats were pre and co-treated with 7-hydroxycoumarin (16 mg/kg body weight) daily for 8 days. Myocardial infarction was induced into rats by the subcutaneous administrat...detailed

Incorporation of photoluminescent 7-Hydroxycoumarin (cas 93-35-6) units onto a polyethylene matrix by means of gamma radiation07/20/2019

A 60Co source generating gamma radiations was used to graft polyethylene (PE) films with acryloyl chloride (AC). Different doses of radiations (2, 4, 6 and 8 kGy) were employed in order to obtain polymers with different amount of grafted ramifications. Furthermore, the desired photoluminescent p...detailed

7-Hydroxycoumarin (cas 93-35-6) modulates the oxidative metabolism, degranulation and microbial killing of human neutrophils07/21/2019

In the present study, we assessed whether 7-hydroxycoumarin (umbelliferone), 7-hydroxy-4-methylcoumarin, and their acetylated analogs modulate some of the effector functions of human neutrophils and display antioxidant activity. These compounds decreased the ability of neutrophils to generate su...detailed

Hepatoprotective effect of 7-Hydroxycoumarin (cas 93-35-6) against Methyl glyoxal toxicity via activation of Nrf207/19/2019

Methyl glyoxal (MG), a major precursor of advanced glycation end-products, has been identified as significant in the progression of several diseases including aging, diabetes and neurodegenerative diseases as well as causing hepatic damages. 7-hydroxycoumarin (7-HC), a natural-occurring derivati...detailed

Combination of 7-Hydroxycoumarin (cas 93-35-6) in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action07/18/2019

A novel compound, Cou-platin, composed of 7-hydroxycoumarin and a platinum(IV) moiety derived from cisplatin was designed and synthesized. Significantly, Cou-platin exhibited more potent in vitro antitumor activity against all tested cancer cell lines than that of cisplatin, which was mainly att...detailed

Structural investigation of Cu(II) complexes with dibromo 7-Hydroxycoumarin (cas 93-35-6) derivatives using methodology based on XAS07/17/2019

Two new copper(II) complexes based on 6/8-acetyl-3,8/6-dibromo-7-hydroxy-4-methylcoumarin have been synthesized and structurally characterized. The electrochemical synthesis has been applied to enforce the complexation reaction. Characterization of non-crystalline product have been performed usi...detailed

Synthesis and evaluation of bi-functional 7-Hydroxycoumarin (cas 93-35-6) platinum(IV) complexes as antitumor agents07/16/2019

A series of bi-functional 7-hydroxycoumarin platinum(IV) complexes were synthesized, characterized, and evaluated for antitumor activities. The 7-hydroxycoumarin platinum(IV) complexes display moderate to effective antitumor activities toward the tested cell lines and show much potential in over...detailed

Inhibition of human cytochrome P450 2A6 by 7-Hydroxycoumarin (cas 93-35-6) analogues: Analysis of the structure-activity relationship and isoform selectivity07/15/2019

Compared with coumarin, 7-hydroxycoumarin could serve as a better hit for developing CYP2A6 inhibitors. In this study, a series of 7-hydroxycoumarin and its structural analogues were collected to study their structure-activity relationship (SAR) and isoform selectivity for inhibiting CYP2A6. All...detailed

93-35-6Relevant articles and documents

Fluorescence detection of hydroxyl radical generated from oxygen reduction on Fe/N/C catalyst

Chen, Li-Na,Yu, Wen-Song,Wang, Tao,Yang, Xiao-Dong,Yang, Hui-Juan,Chen, Zhi-Xin,Wang, Tan,Tian, Na,Zhou, Zhi-You,Sun, Shi-Gang

, p. 198 - 202 (2020)

Pyrolyzed Fe/N/C catalyst has been considered as the most promising candidate to replace Pt for oxygen reduction reaction (ORR) in fuel cells. However, poor stability of Fe/N/C catalyst, mainly attributed to the oxidation corrosion by aggressive ?OH radical, severely hampers its applications. However, the exact mechanism for generation of ?OH is unclear yet. Herein, we developed a fluorescent method to effectively detect ?OH generated from ORR on Fe/N/C catalyst by using coumarin as a fluorescent probe. A great difference in potential dependence between ?OH and H2O2 generated from the ORR was observed, which suggests that ?OH is not generated from the decomposition of H2O2 as traditional viewpoint.

Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35)

Han, Songhee,Choi, Seunghye,Chun, Young-Jin,Yun, Chul-Ho,Lee, Chang Hoon,Shin, Hee Jung,Na, Han Sung,Chung, Myeon Woo,Kim, Donghak

, p. 394 - 399 (2012)

Cytochrome P450 2A6 (CYP2A6) catalyzes important metabolic reactions of many xenobiotic compounds, including coumarin, nicotine, cotinine, and clinical drugs. Genetic polymorphisms of CYP2A6 can influence its metabolic activities. This study analyzed the functional activities of six CYP2A6 allelic variants (CYP2A6*5,*7,*8,*18,*19, and *35) containing nonsynonymous single-nucleotide polymorphisms. Recombinant variant enzymes of CYP2A6*7,*8,*18,*19, and *35 were successfully expressed in Escherichia coli and purified. However, a P450 holoenzyme spectrum was not detected for the CYP2A6*5 allelic variant (G479V). Structural analysis shows that the G479V mutation may alter the interaction between the A helix and the F-G helices. Enzyme kinetic analyses indicated that the effects of mutations in CYP2A6 allelic variants on drug metabolism are dependent on the substrates. In the case of coumarin 7-hydroxylation, CYP2A6*8 and *35 displayed increased Km values whereas CYP2A6*18 and *19 showed decreased kcat values, which resulted in lower catalytic efficiencies (kcat/Km). In the case of nicotine 5-oxidation, the CYP2A6*19 variant exhibited an increased Km value, whereas CYP2A6*18 and *35 showed much greater decreases in kcatvalues. These results suggest that individuals carrying these allelic variants are likely to have different metabolisms for different CYP2A6 substrates. Functional characterization of these allelic variants of CYP2A6 can help determine the importance of CYP2A6 polymorphisms in the metabolism of many clinical drugs.

Synthesis of 7-hydroxycoumarins catalysed by solid acid catalysts

Hoefnagel,Gunnewegh,Downing,Van Bekkum

, p. 225 - 226 (1995)

Syntheses of substituted 7-hydroxycoumarins via reactions of 1,3-dihydroxybenzene with ethyl acetoacetate (Pechmann reaction) and with propenoic acid and propynoic acids are reported, in which the production of environmentally harmful waste streams is minimized by the use of solid acid catalysts.

Sn-Doped defect pyrochlore oxide KNbWO6·H2O microcrystals and their photocatalytic reduction of CO2

Zeng, Xu,Chen, Yan,Jiao, Shihui,Fang, Zhenxing,Wang, Boran,Pang, Guangsheng,Feng, Shouhua

, p. 5753 - 5758 (2018)

It is highly desirable to develop new semiconductors for the photocatalytic reduction of CO2 to CH4 and CO to solve greenhouse effect and energy issues. Defect pyrochlore oxides have a flexible composition and the electron/hole mobility can be manipulated by introducing foreign cations into the structure. Through Sn doping into the defect pyrochlore oxide KNbWO6·H2O, we successfully obtained a 2-times higher photocatalytic activity for converting CO2 to CO, CH4 and O2 compared to the original KNbWO6·H2O. According to the data from UV-vis, photoluminescence, and hydroxyl radical amount-related fluorescence spectra, and CO2 adsorption, the improved photocatalytic activity can be attributed to the extended visible light response, the enhanced charge separation and the improved CO2 adsorption due to Sn doping. Our results provide a new strategy for developing high-performance photocatalysts.

LICRED: A versatile drop-in vector for rapid generation of redox-self-sufficient cytochrome P450s

Sabbadin, Federico,Hyde, Ralph,Robin, Aelig,Hilgarth, Eva-Maria,Delenne, Marie,Flitsch, Sabine,Turner, Nicholas,Grogan, Gideon,Bruce, Neil C.

, p. 987 - 994 (2010)

Cytochromes P450 (P450s) are a family of haem-containing oxidases with considerable potential as tools for industrial biocatalysis. Organismal genomes are revealing thousands of gene sequences that encode P450s of as yet unknown function, the exploitation of which will require high-throughput tools for their isolation and characterisation. In this report, a ligation-independent cloning vector "LICRED" is described that enables the high-throughput generation of libraries of redox-self-sufficient P450s by fusing a range of P450 haem domains to the reductase of P450RhF (RhF-Red) in a robust and generically applicable way. Cloning and expression of fusions of RhF-Red with the haem domains of P450cam and P450-XplA resulted in soluble, active, redox-self-sufficient, chimeric enzymes. In vitro studies also revealed that electron transfer from NADPH to haem was primarily intramolecular. The general applicability of the LICRED platform was then demonstrated through the creation of a library of RhF-Red fusion constructs by using the diverse complement of P450 haem domains identified in the genome of Nocardia farcinica. The resultant fusion-protein library was then screened against a panel of substrates; this revealed chimeric enzymes competent for the hydroxylation of testosterone and methyltestosterone, and the dealkylation of 7-ethoxycoumarin.

-

Pandya,Sodhi

, p. 381 (1938)

-

Microwave Synthesis of Spinel MgFe2O4Nanoparticles and the Effect of Annealing on Photocatalysis

McDonald, Kori D.,Bartlett, Bart M.

, p. 8704 - 8709 (2021)

Through microwave heating in ethanol and with subsequent annealing, crystalline MgFe2O4 nanoparticles are produced rapidly and in high yields >99%. Under varied annealing temperatures, the degree of Mg and Fe site inversion changes the optical, electronic, and composition of the nanoparticles. A small particle size of ~10 nm is achievable with the aid of an ammonium salt mineralizer that caps the particles during nucleation and growth. Particles with the lowest inversion parameter and limited sintering upon annealing (at 600 °C) exhibit the greatest production of hydroxyl radicals under visible light illumination. As such, these particles also facilitate the degradation of methylene blue dye faster than those particles annealed at higher temperature and show a rate constant of 0.061 h-1 for degrading 10 ppm methylene blue with 20 mg of catalyst.

-

Kir'yalov

, (1967)

-

Improved photoactivities for CO2 conversion and phenol degradation of α-Fe2O3 nanoparticles by co-coupling nano-sized BiPO4 and CuO to modulate electrons

Chen, Shuangying,Mu, Zhiyuan,Yan, Rui,Zhang, Xuliang,Khan, Iltaf,Li, Zhijun,Sun, Ning,Zhang, Qingyang,Jing, Liqiang

, p. 231 - 239 (2019)

It's highly desired to design and fabricate effective α-Fe2O3-based photocatalysts by increasing the surface area, promoting the charge separation and providing catalytic function. Herein, specific surface area-enlarged α-Fe2O3 (SE-FO) nanoparticles have been successfully synthesized by a functional molecule-modulated phase-separated hydrothermal method, with high photocatalytic activities for CO2 conversion and phenol degradation. The photocatalytic activities of SE-FO could be greatly improved by coupling nano-sized BiPO4 via an in-situ introduction method. This is attributed to the coupled BiPO4 as a high-energy platform to accept photogenerated electrons from α-Fe2O3 so as to enhance the charge separation mainly by means of surface photovoltage spectra and fluorescence spectra-related to the amount of produced ?OH species. Moreover, the photocatalytic activities are further improved by introducing a proper amount of nanocrystalline CuO via a simple impregnation process. It is confirmed based on the temperature-programmed desorption and electrochemical reduction measurements that the improved photoactivity is attributed to the introduced CuO as the co-catalyst for promoting electron-induced reduction reactions. Remarkably, the optimized α-Fe2O3 nanocomposite exhibits about 3-time photoactivity improvement compared with the pristine α-Fe2O3. This work would provide a feasible route to fabricate high-activity α-Fe2O3-based photocatalysts for CO2 conversion and phenol degradation.

Development of a highly selective H2S fluorescent probe and its application to evaluate CSE inhibitors

Gu, Xianfeng,Zhu, Huikun,Yang, Suna,Zhu, Yi-Chun,Zhu, Yi-Zhun

, p. 50097 - 50101 (2014)

In this paper, we developed a novel fluorescent probe C359 for highly selective detection of H2S over other relevant biothiols. C359 is designed to contain a thiol-specific cleavable disulfide bond. H2S-mediated the disulfide cleavage and subsequent intramolecular cyclization released the masked 7-hydroxyl coumarin, displaying a remarkable fluorescence enhancement. With the promising features in hand, C359 has been applied to detect the activity of CSE (one of H2S-producing enzyme) and build up an assay for screening CSE inhibitors. We anticipated that the enzyme assay using C359 could provide a powerful methodology for screening more potent and selective enzyme inhibitors. This journal is

Fluorogenic Cyanohydrin Esters as Chiral Probes for Esterase and Lipase Activity

Leroy, Emmanuel,Bensel, Nicolas,Reymond, Jean-Louis

, p. 859 - 865 (2003)

Fluorogenic cyanohydrin esters were prepared that release the fluorescent product umbelliferone by secondary decomposition of the primary cyanohydrin reaction product by cyanide elimination to the aldehyde and subsequent β-elimination. Whereas butyrate 1b and octanoate 1d show the highest reaction rates with enzymes, the highest relative rates above the non-catalyzed background reaction are achieved with pivalate 1c and benzoate 1e. Enantioselective reactions are detected when the conversion stabilizes at 50% of the maximum fluorescence release, and enantioselectivity is confirmed by chiral-phase HPLC analysis of the unreacted cyanohydrin ester substrate.

Co-MOF as an electron donor for promoting visible-light photoactivities of g-C3N4 nanosheets for CO2 reduction

Chen, Qiuyu,Li, Sijia,Xu, Hongyi,Wang, Guofeng,Qu, Yang,Zhu, Peifen,Wang, Dingsheng

, p. 514 - 523 (2020)

A possible mechanism for boosting the visible-light photoactivities of graphitic carbon nitride (g-C3N4) nanosheets for CO2 reduction via coupling with the electron donor Co-metal-organic framework (MOF) is proposed in this study. Specifically, Co-MOF as an electron donor is capable of transferring the photogenerated electrons in the lowest unoccupied molecular orbital (LUMO) to the conduction band of g-C3N4 to facilitate charge separation. As expected, the prepared Co-MOF/g-C3N4 nanocomposites display excellent visible-light-driven photocatalytic CO2 reduction activities. The CO production rate of 6.75 μmol g?1 h?1 and CH4 evolution rate of 5.47 μmol g?1 h?1 are obtained, which are approximately 2 times those obtained with the original g-C3N4 under the same conditions. Based on a series of analyses, it is shown that the introduction of Co-MOF not only broadens the range of visible-light absorption but also enhances the charge separation, which improves the photocatalytic activity of g-C3N4 to a higher level. In particular, the hydroxyl radical (?OH) experiment was operated under 590 nm (single-wavelength) irradiation, which further proved that the photogenerated electrons in the LUMO of Co-MOF can successfully migrate to g-C3N4. This work may provide an important strategy for the design of highly efficient g-C3N4-based photocatalysts for CO2 reduction.

Drastic enhancement on Fenton oxidation of organic contaminants by accelerating Fe(III)/Fe(II) cycle with l-cysteine

Luo, Lianshun,Yao, Yuyuan,Gong, Fei,Huang, Zhenfu,Lu, Wangyang,Chen, Wenxing,Zhang, Li

, p. 47661 - 47668 (2016)

The development of a highly efficient and pH-tolerant Fenton system has been one of the most important and challenging goals in water remediation. Herein, a green natural organic ligand, l-cysteine (Cys), was innovatively introduced into Fenton's reagent to construct an excellent catalytic oxidation system. The introduction of Cys into the Fenton system expanded the effective pH range up to 6.5 and achieved a superior oxidation efficiency, representing about 70% higher removal ratio and 12 times higher reaction rate constant with methylene blue dye as the probe compound. The Cys-driven Fenton reaction presented an outstanding pH adaptability and oxidative activity compared with other common organic ligands or reducing agent-modified Fenton reactions. An investigation of the reaction mechanism indicated that the addition of Cys into the system accelerated the Fe(iii)/Fe(ii) cycle, and led to a relatively steady Fe(ii) recovery, which enhances the generation of hydroxyl radicals (OH). The presence of Cys in the Fenton system remarkably reduced the apparent activation energy from 95.90 to 47.93 kJ mol-1. The findings from this study provide a feasible approach for a highly efficient and pH-tolerant wastewater treatment process with environmentally benign characteristics, and initiates an inspiring research domain of amino acids in the environmental catalysis field.

Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations

Shimada,Yamazaki,Guengerich

, p. 395 - 403 (1996)

Interethnic differences in cytochrome P4502A6 (CYP2A6) levels and coumarin 7-hydroxylation activities were determined in liver microsomes of 30 Japanese and 30 Caucasians. Although CYP2A6 levels and coumarin 7-hydroxylation activities varied very significantly in the 60 human samples examined, both CYP2A6 levels and coumarin 7-hydroxylation activities were found to be higher in Caucasian than Japanese population. Interestingly, eight of the 30 Japanese examined showed very low or undetectable levels of coumarin 7-hydroxylation activities as well as of CYP2A6 in liver microsomes. All of the Caucasians, however, had significant CYP2A6 levels and variable 7-hydroxylation activities. Kinetic analysis of coumarin 7-hydroxylation activities in liver microsomes of various human samples suggested that although there were ~260-fold differences in V(max)'s in 10 human samples examined, the K(m)'s were very similar (2.1 ± 0.7 μM); a value consistent with that obtained (1.2 μM) with purified CYP2A6 in reconstituted system. The results suggest that CYP2A6 is actually involved in the 7-hydroxylation of coumarin in human liver microsomes, and that interethnic differences in coumarin 7-hydroxylation activities in Japanese and Caucasian population may be ascribed to the differences in expression of CYP2A6 protein.

Purified fusion enzyme between rat cytochrome P4501A1 and yeast NADPH-cytochrome P450 oxidoreductase

Hara, Masayuki,Miyake, Jun,Asada, Yasuo,Ohkawa, Hideo

, p. 21 - 28 (1999)

A genetically engineered fusion enzyme between rat P4501A1 and yeast P450 reductase in the microsomal fraction of the recombinant yeast AH22/pAFCR1 was purified. The purified enzyme showed a typical CO-difference spectrum of P4501A1 and a single band with an apparent molecular weight of 125,000 on sodium dodecyl sulfate polyacrylamide gel electrophoresis. This agreed with the molecular weight of 131,202 calculated from the amino acid sequence. The purified enzyme showed both 7-ethoxycoumarin o-deethylase activity and horse heart cytochrome c reductase activity in the presence of NADPH. The 7-ethoxycoumarin o-deethylase activity depended on the species of lipid used for the reconstitution of the purified fusion enzyme although the purified enzyme showed the activity without reconstitution. The purified fusion enzyme had the Km value of 26 μM for 7-ethoxycoumarin and the maximal turnover rate of 29 mol product/min/mol enzyme at 30°C.

7-Ethoxycoumarin O-deethylase kinetics in isolated rat, dog and human hepatocyte suspensions

Bayliss,Bell,Wilson,Park

, p. 231 - 241 (1994)

A comparative study of the kinetics of the O-deethylation of 7-ethoxycoumarin has been carried out in freshly isolated rat, dog and human hepatocytes. Biphasic kinetics were observed for all three species with apparent K(m) and V(max) values of 11.5, 2.2 and 3.9 μM and 0.30, 0.21, 0.007 nmol/min/106 cells from rat, dog and man, respectively, for the high affinity-low capacity component, and 560, 40, 470 μM and 1.52, 0.74, 0.057 nmol/min/106 cells, respectively, for the low affinity-high capacity component. These observed kinetic parameters in hepatocytes from rat and man were similar to published values for microsomes for the same two species. Values for intrinsic clearance of 7-ethoxycoumarin for the three species calculated from the K(m) and V(max) data were 152, 631 and 6 ml/min/kg for rat, dog and human hepatocytes, respectively. These intrinsic clearance values predict that 7-ethoxycoumarin would be subject to a high hepatic clearance in rat and dog, and low hepatic clearance in man. These values are supported by published data on rat which show that 7-ethoxycoumarin is subject to high clearance.

-

Kir'yalov

, (1969)

-

Carbon-centered radicals can transfer hydrogen atoms between amino acid side chains

Raffy, Quentin,Buisson, David-Alexandre,Cintrat, Jean-Christophe,Rousseau, Bernard,Pin, Serge,Renault, Jean Philippe

, p. 2960 - 2963 (2012)

Radical migration between aliphatic amino acid side chains can occur in solution and intramolecularly in peptides. The kinetic constant of the hydrogen transfer reaction was measured by using competition kinetics, and the half-life as well as the distance that a radical can move within a protein was calculated. Copyright

-

Zhukov,Prokopenko

, (1967)

-

A sensitive and selective high-throughput screening fluorescence assay for lipases and esterases

Nyfeler, Erich,Grognux, Johann,Wahler, Denis,Reymond, Jean-Louis

, p. 2919 - 2927 (2003)

Long-chain fatty acid esters of 7-(3,4-dihydroxybutyloxy)-2H-1-benzopyran-2-one (6) such as octanoate 2a are shown to be exceptionally sensitive and selective fluorogenic substrates for lipases and esterases. Umbelliferone (8) is released upon hydrolysis of the ester function in 2a in the presence of bovine serum albumin and sodium periodate. These substrates are at least by one order of magnitude more sensitive to lipases than the commercial fluorogenic substrate 4-methylumbelliferyl heptanoate. Furthermore, they are stable to a broad range of pH-induced- and thermal-hydrolysis conditions and do not react with non-catalytic proteins such as bovine serum albumin (BSA).

Preparation and photocatalytic performance of Bi nanoparticles by microwave-assisted method using ascorbic acid as reducing agent

Cui, Zhankui,Zhang, Yange,Li, Senlin,Ge, Suxiang

, p. 97 - 100 (2015)

Bismuth nanoparticles (NPs) were prepared by using microwave (MW) as heating source and ascorbic acid as reducing agent. Pure phase of Bi NPs was obtained and the size was uniform with the mean value of 70 nm. The visible light absorption was good and the optical band gap was 1.77 eV. The photocatalytic efficiency was 2.7 times that of the sample by solvothermal method for degradation of methyl blue (MB) under visible light irradiation. The hydroxyl radicals during photocatalysis were detected due to the transition of Bi from semimetal to semiconductor. The small size effect was considered to contribute a lot to the efficient photocatalytic activity.

In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole

Sasabe, Hiroyuki,Koga, Toshihisa,Furukawa, Masayuki,Matsunaga, Masayuki,Sasahara, Katsunori,Hashizume, Kenta,Oozone, Yoshihiro,Amunom, Immaculate,Torii, Mikako,Umehara, Ken,Kashiyama, Eiji,Takeuchi, Kenji

supporting information, p. 522 - 535 (2021/03/19)

Brexpiprazole, a serotonin-dopamine activity modulator, is indicated for the treatment of schizophrenia and also adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder. To determine the drug–drug interaction risk for cytochrome P450, and SLC and ABC transporters, brexpiprazole and its metabolite, DM-3411 were assessed in this in?vitro investigation. Brexpiprazole exhibited weak inhibitory effects (IC50 >13 μmol/L) on CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activities, but had moderate inhibitor activity on CYP2B6 (IC50 8.19 μmol/L). The ratio of systemic unbound concentration (3.8 nmol/L) to the Ki value was sufficiently low. DM-3411 had comparable inhibitory potentials with brexpiprazole only for CYP2D6 and CYP3A4. The mRNA expressions of CYP1A2, CYP2B6 and CYP3A4 were not changed by the exposure of brexpiprazole to human hepatocytes. Brexpiprazole and DM-3411 exhibited weak or no inhibitory effects for hepatic and renal transporters (OATPs, OATs, OCTs, MATE1, and BSEP), except for MATE-2K (0.156 μmol/L of DM-3411), even for which the ratio to systemic unbound concentration (5.3 nmol/L) was sufficiently low. Brexpiprazole effected the functions of P-gp and BCRP with IC50 values of 6.31 and 1.16 μmol/L, respectively, however, the pharmacokinetic alteration was not observed in the clinical concomitant study on P-gp and BCRP substrates. These in?vitro data suggest that brexpiprazole is unlikely to cause clinically relevant drug interactions resulting from the effects on CYPs or transporters mediating the absorption, metabolism, and/or disposition of co-administered drugs.

Boronic acid with high oxidative stability and utility in biological contexts

Graham, Brian J.,Windsor, Ian W.,Gold, Brian,Raines, Ronald T.

, (2021/03/16)

Despite their desirable attributes, boronic acids have had a minimal impact in biological contexts. A significant problem has been their oxidative instability. At physiological pH, phenylboronic acid and its boronate esters are oxidized by reactive oxygen species at rates comparable to those of thiols. After considering the mechanism and kinetics of the oxidation reaction, we reasoned that diminishing electron density on boron could enhance oxidative stability. We found that a boralactone, in which a carboxyl group serves as an intramolecular ligand for the boron, increases stability by 104-fold. Computational analyses revealed that the resistance to oxidation arises from diminished stabilization of the p orbital of boron that develops in the rate-limiting transition state of the oxidation reaction. Like simple boronic acids and boronate esters, a boralactone binds covalently and reversibly to 1,2-diols such as those in saccharides. The kinetic stability of its complexes is, however, at least 20-fold greater. A boralactone also binds covalently to a serine side chain in a protein. These attributes confer unprecedented utility upon boralactones in the realms of chemical biology and medicinal chemistry.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 93-35-6